Pluristem picks CRO for cancer PhI trial, but can’t say who it has chosen

Research

Israeli biotech Pluristem Therapeutics has chosen a “leading, global” CRO to help run its Phase I blood cancer trial--but the company is a little shy on publicity, as it does not want to be named.

In a statement, Pluristem said it is pushing on with the Phase I trial of its experimental treatment using PLX-R18 cells to treat insufficient hematopoietic recovery following hematopoietic cell transplantation by “contracting with a leading global clinical research organization.”

Who? Well, we can’t know. Pluristem told FierceCRO that: “The CRO has a policy not to release their name in publicity by a client, so I am not able to tell you.” So for now, it’s a secret.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

But despite not being in the press release, it will be on hand for the study, which has recently been cleared by the FDA to focus on the safety of the treatment that will consist of intramuscular injections of PLX-R18 cells in 30 patients with incomplete hematopoietic recovery persistent for 6 months or more after HCT. The trial is set to start later this year.

Pluristem Chairman and CEO Zami Aberman said: “Data from this trial will inform the potential of PLX-R18 to treat a wide range of indications including blood cancers and radiation therapy-related blood diseases.”

But Aberman, not able to name names, added: “The CRO we chose has extensive experience working with leading pharmaceutical and biotech companies to successfully manage clinical trials.”

- check out the release

Related Articles:
Pluristem snags spot on EMA's nascent fast-track scheme
Pluristem PLX cells turn around near fatal bone marrow failure

Suggested Articles

Flatiron has hired a new chief medical officer as it looks to push on under its new parent in the world of electronic health records and real-world data.

Medidata is being bought by France’s Dassault Systemes in a deal designed to help the tech firm diversify deeper into the biopharma services world.

Synlogic has tapped Ginkgo Bioworks for a cell programming platform to support development of its pipeline of engineered microbes.